A comparison of buprenorphine + naloxone to buprenorphine and methadone in the treatment of opioid dependence during pregnancy: Maternal and neonatal outcomes

Substance Abuse: Research and Treatment

Volumn 7, Issue , 2013, Pages 61-74

  Lund, Ingunn O ^a   Fischer, Gabriele ^b   Welle Strand, Gabrielle K ^a   O'grady, Kevin E ^c   Debelak, Kimber ^d   Morrone, William R ^e   Jones, Hendrée E ^f,g  

^a UNIVERSITY OF OSLO   (Norway)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF MARYLAND   (United States)

^d Recovery Pathways   (United States)

^e Children's Hospital of Michigan   (United States)

^f RTI INTERNATIONAL   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Buprenorphine; Methadone; Neonates; Opioid dependence; Pregnancy

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; METHADONE;

ARTICLE; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; FETUS DEVELOPMENT; HEAD CIRCUMFERENCE; HUMAN; LENGTH OF STAY; MATERNAL AGE; OPIATE ADDICTION; PREGNANT WOMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

EID: 84875149086     PISSN: 11782218     EISSN: None     Source Type: Journal    
DOI: 10.4137/SART.S10955     Document Type: Article

References (30)

1. Blinick G. Menstrual function and pregnancy in narcotics addicts treated with methadone. Nature. 1968;219:180.
2. Fischer G, Ortner R, Rohrmeister K, et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction. 2006;101(2):275-281.
3. Jones HE, Johnson RE, Jasinski DR, et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug and Alcohol Dependence. 2005;79(1):1-10.
4. Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. New England Journal of Medicine. 2010;363(24):2320-2321.
5. Kakko J, Heilig M, Sarman I. Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug and Alcohol Dependence. 2008;96(1-2):69-78.
6. Lejeune C, Simmat-Durand L, Gourarier L, Aubisson S. Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenophine substitution. Drug and Alcohol Dependence. 2006;82(3):250-257.
7. Siedentopf J, Nagel M, Eßer M, Casteleyn S, Dudenhausen J. Erfahrungen mit der Buprenorphineinstellung und anschliessenden Dosisreduktion im Vergleich zu L-Methadon bei schwangeren Opiatabhängigen. Geburtsh Frauenheilk. 2004;64(7):711-718.
8. Binder T, Vavrinkova B. Prospective randomised comparative study of the effect of buprenorphine, methadone and heroin on the course of pregnancy, birthweight of newborns, early postpartum adaptation and course of the neonatal abstinence syndrome (NAS) in women followed up in the outpatient department. Neuroendocrinology Letters. 2008;29(1):80-86.
9. Colombini N, Elias R, Busuttil M, Dubuc M, Einaudi MA, Bues-Charbit M. Hospital morphine preparation for abstinence syndrome in newborns exposed to buprenorphine or methadone. Pharmacy World and Science. 2008;30(3):227-234.
10. Fischer G, Johnson RE, Eder H, et al. Treatment of opioid-dependent pregnant women with buprenorphine. Addiction. 2000;95(2):239-244.
11. Johnson RE, Jones HE, Fischer G. Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug and Alcohol Dependence. 2003;70(Suppl 2):S87-S101.
12. Schindler SD, Eder H, Ortner R, Rohrmeister K, Langer M, Fischer G. Neonatal outcome following buprenorphine maintenance during conception and throughout pregnancy. Addiction. 2003;98(1):103-110.
13. Whitham JN, Spurrier NJ, Sawyer MG, et al. The effects of prenatal expo- sure to buprenorphine or methadone on infant visual evoked potentials. Neurotoxicology and Teratology. 2010;32(2):280-288.
14. Fudala PJ, Bridge TP, Herbert S, et al. Offce-based treatment of opi- ate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. New England Journal of Medicine. 2003;349(10):949-958.
15. Strain E, Harrison J, Bigelow G. Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble-films. Clinical Pharmacology and Therapeutics. 2011;89(3):443-449.
16. Brunton PJ, Meddle SL, Ma S, Ochedalski T, Douglas AJ, Russell JA. Endogenous opioids and attenuated hypothalamic-pituitary-adrenal axis responses to immune challenge in pregnant rats. The Journal of Neuroscience. 2005;25(21):5117-5126.
17. Douglas A, Meddle S, Toschi N, Bosch O, Neumann I. Reduced activity of the noradrenergic system in the paraventricular nucleus at the end of pregnancy: implications for stress hyporesponsiveness. Journal of Neuroendocrinology. 2005;17(1):40-48.
18. Czerkes M, Blacstone J, Pulvino J. Buprenorphine Versus Methadone Treat- ment for Opiate Addiction in Pregnancy: An Evaluation of Neonatal Outcomes. The American College of Obstetricians and Gynecologists: Papers on Current Clinical and Basic Investigation. 2010; San Fransisco, US.
19. Debelak K, Morrone WR, O'Grady KE, Jones HE. Buprenorphine + Naloxone in the Treatment of Opioid Dependence during Pregnancy: Initial Patient Care and Outcome Data. American Journal on Addictions. 2012. In press.
20. Jones HE, O'Grady KE, Malf D, Tuten M. Methadone maintenance vs. methadone taper during pregnancy: maternal and neonatal outcomes. The American Journal on Addictions. 2008;17(5):372-386.
21. Metz V, Jagsch R, Ebner N, et al. Impact of treatment approach on maternal and neonatal outcome in pregnant opioid-maintained women. Human Psychopharmacology: Clinical and Experimental. 2011;26(6): 412-421.
22. Jones HE, Heil SH, Baewert A, et al. Buprenorphine treatment of opioid- dependent pregnant women: a comprehensive review. Addiction. 2012; 107(Suppl 1):5-27.
23. Jones HE, Fischer G, Heil S, et al. Maternal Opioid Treatment: Human Experimantal Research (MOTHER)-approach, issues, and lessons learned. Addiction. 2012;107(Suppl 1):28-35.
24. Firth D. Bias reduction of maximum likelihood estimates. Biometrika. 1993;80(1):27-38.
25. Larson DA. Analysis of variance with just summary statistics as input. American Statistician. 1992;46(2):151-152.
26. WHO Multicentre Growth Reference Study Group. WHO Child Growth Standards: Length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: Methods and development. Geneva: World Health Organization; 2006. Available at: http://www.who. int/childgrowth/standards/technical_report/en/. Accessed Feb 2, 2013.
27. Kaltenbach K, Berghella V, Finnegan L. Opioid dependence during preg- nancy. Effects and management. Obstetrics and Gynecology Clinics of North America. 1998;25(1):139-151.
28. American Academy of Pediatrics, Committee on Fetus and Newborn, American College of Obstetricians and Gynecologists, Committee on Obstetric Practice. The Apgar Score. Pediatrics, 2006;117:1444-1447.
29. Jones HE, Kaltenbach K, Heil SH, et al. Intrauterine abstinence syndrome (IAS) during buprenorphine inductions and methadone tapers: can we assure the safety of the fetus? Journal of Maternal-Fetal and Neonatal Medicine. 2012;25(7):1197-1201.
30. Bakstad B, Welle-Strand, G. Nasjonal retningslinje for gravide i legemid- delassistert rehabilitering (LAR) og oppfølging av familiene frem til barnet når skolealder [Only in Norwegian: National guidelines for pregnant women in opioid maintenance treatment (OMT) and follow-up of their families until the children reach school age]. Oslo, Norway: Norwegian Directorate of Health; 2011.